Mark Opdam

6PUBLICATIONS
76CO-AUTHORS
Predictive and prognostic markersMolecular targetsInnate immunitySolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 30, 2023
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

Stefan Prekovic, Theofilos Chalkiadakis, Merel Roest

|Aug 29, 2023
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

Jinhyuk Bhin, Julia Yemelyanenko, Xue Chao

|May 25, 2023
Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studies.

Gregory Verghese, Mengyuan Li, Fangfang Liu

|Mar 30, 2022
Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.

Vincent M T de Jong, Yuwei Wang, Natalie D Ter Hoeve

|Feb 06, 2022
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.

Leonora W de Boo, Katarzyna Jóźwiak, Heikki Joensuu

|Dec 30, 2021
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

Lennart Kester, Danielle Seinstra, Annelot G J van Rossum

Pageof 1

Frequent Collaborators

3 joint publications

Sabine C Linn

2 joint publications

Jos Jonkers

2 joint publications

Liesbeth Hoekman

2 joint publications

Michael Hauptmann